Muscle News and Research

RSS

Study finds prevalence of low vitamin D status among obese adolescents

A new study from Hasbro Children's Hospital has found that most obese adolescents are lacking in vitamin D.

28 Apr 2011

FDA approves BIOTRONIK's new Estella and Effecta pacemakers

BIOTRONIK, a leading manufacturer of implantable cardiac devices and pioneer of wireless remote monitoring technologies, today announced FDA approval of the new Estella and Effecta pacemakers, as well as advanced new features and technologies for the Evia pacemaker family.

28 Apr 2011

JumpStart Ventures invests $250,000 in SPR Therapeutics

JumpStart Ventures, a nonprofit that invests in and partners with innovative, early-stage companies in Northeast Ohio, announced an investment commitment of $250,000 in SPR Therapeutics.

27 Apr 2011

Researchers investigate new device that can recognize early heart attack signs

When a heart attack begins, a stopwatch starts. With each passing minute heart tissue is deprived of blood, causing it to deteriorate or die. In order to minimize damage to the heart, blood flow must be restored promptly, or the effects can be serious, often even fatal.

27 Apr 2011

Lilly and Medtronic’s joint venture in Parkinson’s disease therapy

Lilly has already developed a protein called GDNF (glial cell line derived neurotrophic factor) known to preserve the function of neurons and Medtronic will provide a system that carries the medicine to a key area of the brain.

From Medtronic 26 Apr 2011

Botox injections: Reading and mimicking emotions hampered

In cosmetics, a Botox injection, consisting of a small dose of botulinum toxin, can be used to prevent formation of wrinkles by paralyzing facial muscles and can therefore make users appear less emotional. Now a new study finds that the cosmetic toxin may also make recipients less able to read the emotions of others.

26 Apr 2011

Researchers report game-changing advance in stem cell science

In a paper published in the April 25 early online edition of the Proceedings of the National Academy of Sciences, researchers at the University of California, San Diego School of Medicine, the Gladstone Institutes in San Francisco and colleagues report a game-changing advance in stem cell science: the creation of long-term, self-renewing, primitive neural precursor cells from human embryonic stem cells that can be directed to become many types of neuron without increased risk of tumor formation.

26 Apr 2011

New discoveries in stem-cell technology

A scientist at the Gladstone Institutes has made two significant stem-cell discoveries that advance medicine and human health by creating powerful new approaches for using stem cells and stem-cell-like technology.

26 Apr 2011

Study: HIV infection linked to increased risk of heart failure

Patients with HIV infection without a prior history of coronary heart disease may be at a higher risk of developing heart failure, according to a report in the April 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

26 Apr 2011

XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis

XenoPort, Inc. announced today that it had reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for a pivotal Phase 3 clinical trial of arbaclofen placarbil, previously known as XP19986, as a potential treatment of spasticity in multiple sclerosis patients.

25 Apr 2011

New book on aging

Aging is a natural part of life. From the minute we are born we are heading in one certain direction: towards death. That said, it is possible to arrive at that ultimate destination graceful and vital to our last days rather than chronically ill suffering from one or many debilitating illnesses.

25 Apr 2011

Scientists discover new mechanism behind Salmonella invasion into gut cells

Scientists from the Helmholtz Centre for Infection Research in Braunschweig, Germany have discovered a new, hitherto unknown mechanism of Salmonella invasion into gut cells: In this entry mode, the bacteria exploit the muscle power of cells to be pulled into the host cell cytoplasm.

22 Apr 2011

First UCLA patient with hand transplant doing well at six-and-a-half weeks

Six-and-a-half weeks after receiving the first hand transplant in the western United States, Emily Fennell is becoming so accustomed to her new right hand that she barely remembers when she didn't have one.

21 Apr 2011

Repligen anticipates 30% increase in total revenues for 2011

Repligen Corporation today announced preliminary financial results for fiscal year 2011 which ended March 31, 2011. Total revenue for the year is expected to be $27.3 million compared to $21.0 million in the prior fiscal year, an increase of 30%.

21 Apr 2011

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Salix Pharmaceuticals, Ltd. today announced that the U.S. Patent and Trademark Office has issued three patents relating to rifaximin.

21 Apr 2011

Stealth Peptides launches mitochondrion targeting compound Bendavia at Experimental Biology 2011

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative mitochondrial therapies, introduced its lead clinical candidate, Bendavia™, a novel compound that targets the mitochondrion, during multiple scientific sessions of the Experimental Biology 2011 meeting.

20 Apr 2011

Testosterone therapy for prostate cancer needs reevaluation: New study

The long-standing prohibition against testosterone therapy in men with untreated or low-risk prostate cancer merits reevaluation, according to a new study published in The Journal of Urology.

20 Apr 2011

New state of myosin in cardiac muscle with low ATP turnover rate could decrease metabolic load of myocardium

New insight into the physiology of cardiac muscle may lead to the development of therapeutic strategies that exploit an inherent protective state of the heart. The research, published by Cell Press online on April 19th in the Biophysical Journal, discovers a state of cardiac muscle that exhibits a low metabolic rate and may help to regulate energy use and promote efficiency in this hard-working and vital organ.

20 Apr 2011

Rituxan receives FDA approval for treating two rare diseases

The U.S. Food and Drug Administration today approved Rituxan (rituximab), in combination with glucocorticoids (steroids), to treat patients with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA), two rare disorders that cause blood vessel inflammation (vasculitis).

20 Apr 2011

Treatment commences in NeuroVive-HCL's 1,000 patient European cardioprotection trial

NeuroVive Pharmaceutical and Hospices Civils de Lyon (HCL) today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction (the CIRCUS study). NeuroVive's advanced CicloMulsion(TM) cremophor-free IV cyclosporine formulation is used in this study of 1,000 patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction to examine cyclosporine's ability to protect cardiac tissue.

20 Apr 2011